Microsatellite Instability testing (MSI) [Tissue]
Microsatellite Instability testing testing (FFPE).
Oncogene panel testing [Tissue]
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.
Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
Urothelial/bladder cancer (FGFR SNV/fusions) [Tissue]
FGFR3 testing (SNVs and gene fusions) in Urothelial / Bladder cancer (FFPE)
Pan-Tumour Fusions [FFPE]
Fusion gene testing for fusions relevant to therapy (ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, or FGFR3) for solid cancers (FFPE)
Homologous Recombination Deficiency (HRD) testing in ovarian cancer [Tissue]
HRD testing for Ovarian Cancer (Tissue). This EQA is sponsored.